Disc Medicine, Inc. (IRON)

Disc Medicine (IRON) closed at $79.42, up 0.27% on the day, after trading in a wide range between $74.52 and $80.00 on volume of 1,854,818 shares. The session was marked by a wave of bullish analyst actions, with Morgan Stanley, Truist, Wells Fargo, and Wedbush all reiterating positive ratings and raising their price targets to $92, $115, $124, and $110, respectively. These upgrades suggest growing confidence in the stock's outlook, though the modest close near the middle of the day's range indicates the market may have already priced in some of the optimism. The consistent upward target revisions from multiple firms signal a bullish direction for IRON.

Disc Medicine (IRON) surged 8.57% to close at $78.93 after reporting that its pivotal Phase 3 APOLLO trial of bitopertin in EPP met all primary and secondary goals, a major clinical win for its sunlight sensitivity treatment. The positive data prompted analyst upgrades, with BMO Capital lifting its target to $120 and Cantor Fitzgerald raising its target to $170 while maintaining bullish ratings. Offsetting this optimism, the company also announced plans to raise $350 million through a stock and pre-funded warrant sale, introducing dilution concerns. Despite the capital raise overhang, the strong trial results and analyst target hikes drove the stock sharply higher, signaling a bullish direction.